GeoVax Labs, Inc. reported financial results for the third quarter of 2025 while highlighting substantial progress across its vaccine and oncology development programs. The clinical-stage biotechnology company is advancing multiple vaccine platforms that address urgent global health needs, including the ongoing Mpox emergency and COVID-19 protection for vulnerable populations.
The company accelerated development of its GEO-MVA vaccine in response to the World Health Organization’s reaffirmation of Mpox as a global public health emergency. Favorable scientific advice from the European Medicines Agency supported a streamlined regulatory pathway for GEO-MVA, advancing the company’s goal of becoming a diversified supplier addressing the increasing Mpox threat. A new research collaboration with the University of Queensland and UniQuest will evaluate needle-free delivery using Vaxxas’ high-density microarray patch platform, targeting improved thermostability and dose-sparing performance critical for pandemic preparedness.
For its COVID-19 vaccine program, GeoVax presented encouraging interim data from Phase 2 clinical trials of GEO-CM04S1 at the 6th ESCMID Conference on Vaccines and iwCLL 2025 Workshop. The data confirmed robust T-cell and cross-variant antibody responses in chronic lymphocytic leukemia and hematologic cancer patients, exceeding immune activity demonstrated by standard mRNA vaccines. The CLL trial met its immunogenicity target, prompting discontinuation of the comparator mRNA arm, with sustained cellular responses observed across multiple timepoints indicating long-term protection potential for immunocompromised patients.
In oncology, the company announced plans for a Phase 2 trial evaluating Gedeptin in combination with pembrolizumab and fludarabine in first-line, resectable head and neck squamous cell carcinoma, with initiation targeted for the second half of 2026. Preclinical studies are also expanding into triple-negative breast and cutaneous cancers in collaboration with Emory University’s Winship Cancer Institute.
The company’s U.S.-based MVA platform aligns with bipartisan calls for domestic manufacturing and pandemic preparedness investments. GeoVax’s continuous avian cell line manufacturing process supports legislative goals to modernize domestic biomanufacturing and reduce dependency on foreign vaccine suppliers. The company maintains engagements with multiple global health organizations including ASPR, BARDA, CEPI, Africa CDC, WHO, and UNICEF.
Financially, GeoVax reported a net loss of $6,318,914 for the three-month period ended September 30, 2025, compared to $5,815,468 for the comparable period in 2024. Research and development expenses decreased to $5,043,504 from $7,402,884 in the prior year period, primarily due to discontinued costs associated with termination of the BARDA/RRPV contract and lower clinical trial and manufacturing costs. The company reported cash balances of $5,008,997 at September 30, 2025, compared to $5,506,941 at December 31, 2024. Further information is included in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission available through their official website at https://www.sec.gov.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is GeoVax Advances Vaccine Programs Amid Global Health Crises While Reporting Q3 Financial Results.